Found 5 matching trials
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
PHASE3The purpose of this study is to determine the efficacy of SPD503 compared t...
Location
Multiple Locations
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
PHASE4The main aim of this study is learn more about long-term TAK-503 treatment ...
Location
Harmonex Neuroscience Research
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
PHASE3The purpose of this study is to assess the safety and efficacy of SPD503 (G...
Location
Multiple Locations
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
PHASE3For subjects in Europe that have already participated in either Study SPD50...
Location
Medizinische Universitat Graz Univ fur Kinder
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
PHASE2This study will evaluate the safety and tolerability of SPD503 in subjects ...
Location
Birmingham Research Group, Inc